Cat. No. |
Product Name |
Information |
PC-20531 |
INCB3284 bismesylate
CCR2 antagonist
|
INCB3284 bismesylate (INCB 3284, INCB003284) is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM in antagonism of MCP-1 binding to hCCR2 and 4.7 nM in antagonism of chemotaxis activity. |
PC-20530 |
INCB3284
CCR2 antagonist
|
INCB3284 (INCB 3284, INCB003284) is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM in antagonism of MCP-1 binding to hCCR2 and 4.7 nM in antagonism of chemotaxis activity. |
PC-20525 |
INCB9471
CCR5 antagonist
|
INCB9471 (INCB 9471) is a potent, selective, and orally bioavailable CCR5 antagonist with IC50 of 6.5 nM in MIP-1β assays, exhibits potent anti-HIV-1 activity against ADA and BaL strains with IC50 of 0.36 and 0.16 nM respectively. |
PC-73171 |
USL311
CXCR4 inhibitor
|
USL311 is a potent, selective, orally bioavailable CXCR4 antagonist, with potential antineoplastic activity. |
PC-62992 |
Aplaviroc hydrochloride
|
Aplaviroc (GSK-873140. |
PC-61982 |
CCX-6239
|
CCX-6239 is a novel potent, orally available CCR4 inhibitor with potential utility in the treatment of allergic airways disease.. |
PC-61559 |
PF-04634817 succinate
|
PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. . |
PC-61475 |
Ladarixin sodium
|
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM. |
PC-61301 |
ALT-1188
|
A novel potent, nonpeptide CXCR4 antagonist with IC50 of 0.93 nM. |
PC-61291 |
POL2438
|
A highly potent, selective beta-hairpin mimetic CXCR4 inhibitor with IC50 of 1.9 nM in Ca2+ flux assay. |
PC-61290 |
POL3026
|
A highly potent, selective beta-hairpin mimetic CXCR4 inhibitor with IC50 of 1.2 nM in Ca2+ flux assay. |
PC-45834 |
MK-0812 succinate
|
A potent CCR2 specific antagonist that blocks MCP-1 mediated response with an IC50 of 3.2 nM. |